Johnson & Johnson's DARZALEX (daratumumab) Subcutaneous-Based Regimen Receives Positive CHMP Opinion for Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
March 01, 2025
March 01, 2025
NEW BRUNSWICK, New Jersey, March 1 -- Johnson and Johnson issued the following news release:
* * *
Johnson & Johnson's DARZALEX (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundationa . . .
* * *
Johnson & Johnson's DARZALEX (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundationa . . .